Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
20 Febrero 2024 - 6:14AM
Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)
(“Clearmind” or the "company"), a biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, announced today that
it has submitted three patent applications under the international
Patent Cooperation Treaty ("PCT"), as part of its ongoing
collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"), a
specialty clinical-stage pharmaceutical company focusing on the
development of therapies to treat disorders of the central nervous
system.
The three patent applications refer to novel proprietary
combinations of lysergic acid diethylamide (LSD), psilocybin,
N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide
(PEA), the active ingredient of SciSparc' proprietary
CannAmide™.
These applications were previously filed as provisional patent
applications with the United States Patent and Trademark Office
(USPTO).
"Clearmind continues to be at the forefront of the psychedelic
market with one of the largest IP portfolios in the industry. The
PCT makes it possible for us to seek patent protection for our
proprietary compounds in a large number of countries simultaneously
which strengthens our IP portfolio. To date, our ongoing
collaboration with SciSparc has led to the submission of 11
different patent applications, allowing us to continue to be at the
forefront of research in the psychedelic industry while working on
more effective and safer treatments," said Clearmind’s Chief
Executive Officer, Dr. Adi Zuloff-Shani.
The latest patent applications build upon Clearmind’s broad IP
protection in the psychedelic space, which now includes 27 granted
patents and 24 pending patent applications across 15 patent
families, nine of which have been granted in major jurisdictions
such as the US, Europe, China, and India.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company
focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual portfolio currently consists of
fifteen patent families. The Company intends to seek additional
patents for its compounds whenever warranted and will remain
opportunistic regarding the acquisition of additional intellectual
property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the
Canadian Securities Exchange under the symbol "CMND" and the
Frankfurt Stock Exchange under the symbol “CWY.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relations invest@clearmindmedicine.com Telephone: (604)
260-1566 US: CMND@crescendo-ir.com
General Inquiries Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses seeking patent
protection for its inventions in a large number of countries
simultaneously and continuing to strengthen its IP portfolio. In
addition, the Company cannot assure that any patent will issue as a
result of a pending patent application or, if issued, whether it
will issue in a form that will be advantageous to the Company.
Forward-looking statements are not historical facts, and are based
upon management’s current expectations, beliefs and projections,
many of which, by their nature, are inherently uncertain. Such
expectations, beliefs and projections are expressed in good faith.
However, there can be no assurance that management’s expectations,
beliefs and projections will be achieved, and actual results may
differ materially from what is expressed in or indicated by the
forward-looking statements. Forward-looking statements are subject
to risks and uncertainties that could cause actual performance or
results to differ materially from those expressed in the
forward-looking statements. For a more detailed description of the
risks and uncertainties affecting the Company, reference is made to
the Company’s reports filed from time to time with the Securities
and Exchange Commission (“SEC”), including, but not limited to, the
risks detailed in the Company’s annual report on Form 20-F filed
with the SEC on January 29, 2024. Forward-looking statements speak
only as of the date the statements are made. The Company assumes no
obligation to update forward-looking statements to reflect actual
results, subsequent events or circumstances, changes in assumptions
or changes in other factors affecting forward-looking information
except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no
inference should be drawn that the Company will make additional
updates with respect thereto or with respect to other
forward-looking statements. References and links to websites have
been provided as a convenience, and the information contained on
such websites is not incorporated by reference into this press
release. Clearmind is not responsible for the contents of
third-party websites.
Clearmind Medicine (NASDAQ:CMND)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Clearmind Medicine (NASDAQ:CMND)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024